Further plans for expansion in Europe include up to ten clinical trial sites across Spain by end of Q32022 and up to three sites in Italy by end of 2022 Zelpultide alfa has been approved as the generic name for our AT-100 (rhSP-D) by the two governing organizations, the United States Adopted Names (USAN) Council …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, GEORGIA (March 31, 2022) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, …
Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
Authors: Michael DePietro and Marc Salzberg, Airway Therapeutics, Marietta, GA, United States A Commentary on Pattern Recognition Proteins: First Line of Defense Against Coronaviruses By Labarrere CA and Kassab GS (2021). Front. Immunol. 12:652252. doi: 10.3389/fimmu.2021.652252 Introduction Labarrere and Kassab recently wrote an informative paper that includes a very interesting overview of the role Surfactant …
First patient dosed in startup’s key Covid-19 clinical trial
Airway Therapeutics, a Sharonville-based biopharmaceutical startup, has logged another key milestone in its path toward commercialization. The company, which is developing new interventions for acute and chronic lung diseases, dosed its first patient this month in a new clinical trial aimed at patients severely impacted by Covid-19. The accomplishment is a huge step for the …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
Novel therapeutic AT-100 offers potential to reduce inflammation, associated injury and incidence of secondary infection, and inhibit viral replication and promote viral elimination in severely ill, mechanically-ventilated COVID-19 patients. Initial data readout anticipated in Q4 2021 CINCINNATI, OH (August 26, 2021) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics …
Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2
SARS-CoV-2 infection of host cells is driven by binding of the SARS-CoV-2 spike-(S)-protein to lung type II pneumocytes, followed by virus replication. Surfactant protein SP-D, member of the front-line immune defense of the lungs, binds glycosylated structures on invading pathogens such as viruses to induce their clearance from the lungs. The objective of this study …
Surfactant Protein D and Bronchopulmonary Dysplasia: A New Way to Approach an Old Problem
Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem Surfactant protein D (SP-D) is a collectin protein synthesized by alveolar type II cells in the lungs. SP-D participates in the innate immune defense of the lungs by helping to clear infectious pathogens and modulating the immune response. SP-D has shown …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100’s Second Indication in Severe COVID-19 Patients
Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients CINCINNATI, OH (April 12, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break …
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, OH (March 26, 2021) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to …
Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein
Frontiers | Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways | Bioengineering and Biotechnology (frontiersin.org) This work is focused on the potential use of pulmonary surfactant to deliver full-length recombinant human surfactant protein SP-D (rhSP-D) using the respiratory air-liquid interface as a shuttle. Surfactant protein D (SP-D) …
- 1
- 2
- 3
- 4
- Next Page »
